Pro-Dex Inc
Pro-Dex Inc provides medical equipment, supplies, and distribution services within the healthcare sector, primarily generating revenue through the sale and distribution of medical products and services.
Business. Pro-Dex Inc (PDEX.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Pro-Dex is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Pro-Dex Inc (PDEX.O) has recorded a series of notable new institutional holdings, marking the first analysis for this ticker with no prior basis for delta computation. The most significant addition involves an investor (ID 465) acquiring 144,571 shares valued at approximately $5.56 million as of December 31, 2025. This position represents a weight of roughly 0.008% in the investor's portfolio, signaling a substantial entry into the company's equity structure. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, several investors initiated positions, including one (ID 487) holding 56,941 shares valued at $2.80 million, and another (ID 467) holding 33,114 shares valued at $1.63 million. Smaller but notable entries were also recorded for investors with IDs 499, 486, and 481 during the same quarter, with share counts ranging from 6,493 to 14,213. An earlier addition was noted for an investor (ID 466) who held 38,484 shares valued at $0.76 million as of June 30, 2024. These cumulative additions contribute to a total of 16 top holders currently identified for Pro-Dex Inc. The consistent pattern of "add" changes across different investors and timeframes suggests growing institutional interest in the company's stock. This expansion in the holder base is particularly relevant given the company's current analyst coverage, which stands at just one analyst. With no index membership and zero reported officers in the current dataset, the influx of new institutional capital may serve as a key indicator of market sentiment for Pro-Dex Inc. The accumulation of shares by multiple distinct entities highlights a shift in ownership composition that warrants monitoring for future liquidity and price stability implications.
Signals & dispatch
Composite-score breakdown
Synthesis
Pro-Dex Inc (PDEX.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Pro-Dex is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.
Pro-Dex Inc maintains a relatively strong liquidity position, with a current ratio of 3.23, indicating the company can cover its short-term liabilities more than three times over with its current assets. However, the company's cash and equivalents amount to only $419,000, which is significantly lower than its long-term debt of $15,394,000, resulting in a negative net cash position. This suggests potential liquidity risk if short-term obligations exceed available cash.
The company's profitability metrics are robust, with a return on equity (ROE) of 24.51% and a return on assets (ROA) of 14.67%. These figures exceed the typical thresholds for strong performance in the medical equipment and supplies industry, indicating efficient use of equity and assets to generate profit. The operating margin, calculated as operating income of $10,689,000 on revenue of $66,593,000, is approximately 16.05%, which is in line with industry expectations for firms of similar scale.
Geographically and segment-wise, Pro-Dex Inc's revenue is not disclosed by region or business segment in the available data. However, the company's primary business activity is centered on medical equipment and supplies, which are typically less sensitive to geographic concentration risks compared to other healthcare subsectors. The absence of segment-specific data limits the ability to assess potential overreliance on a single product line or geographic market.
Looking ahead, the company's growth trajectory appears stable, with no specific revenue growth rates provided in the input data. Analysts have assigned a mean price target of $70.00, with a median and high target also at $70.00, suggesting a consensus on the stock's fair value. The mean recommendation of 2.00 (on a scale from 1 to 5) indicates a "buy" rating, with one analyst recommending a "buy" and none recommending a "strong buy" or "strong sell".
Risk factors for Pro-Dex Inc include its negative net cash position, which could limit flexibility in responding to market changes or capital needs. The company's liquidity risk is rated as medium, and while dilution risk is currently low, the absence of a significant equity cushion could expose the company to dilution pressure in the event of a capital raise. No specific dilution sources are disclosed in the input data, but the company's low dilution risk suggests that such events are not imminent.
Recent events and disclosures for Pro-Dex Inc are not detailed in the input data. However, the company's financial performance and analyst ratings suggest a stable outlook, with no immediate signs of distress or volatility. The absence of recent filings or transcripts does not necessarily indicate a lack of activity, but it does limit the ability to assess the company's strategic direction or operational changes in the near term.
Pro-Dex Inc (PDEX.O) has recorded a series of notable new institutional holdings, marking the first analysis for this ticker with no prior basis for delta computation. The most significant addition involves an investor (ID 465) acquiring 144,571 shares valued at approximately $5.56 million as of December 31, 2025. This position represents a weight of roughly 0.008% in the investor's portfolio, signaling a substantial entry into the company's equity structure. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, several investors initiated positions, including one (ID 487) holding 56,941 shares valued at $2.80 million, and another (ID 467) holding 33,114 shares valued at $1.63 million. Smaller but notable entries were also recorded for investors with IDs 499, 486, and 481 during the same quarter, with share counts ranging from 6,493 to 14,213. An earlier addition was noted for an investor (ID 466) who held 38,484 shares valued at $0.76 million as of June 30, 2024. These cumulative additions contribute to a total of 16 top holders currently identified for Pro-Dex Inc. The consistent pattern of "add" changes across different investors and timeframes suggests growing institutional interest in the company's stock. This expansion in the holder base is particularly relevant given the company's current analyst coverage, which stands at just one analyst. With no index membership and zero reported officers in the current dataset, the influx of new institutional capital may serve as a key indicator of market sentiment for Pro-Dex Inc. The accumulation of shares by multiple distinct entities highlights a shift in ownership composition that warrants monitoring for future liquidity and price stability implications.
- Pro-Dex Inc has a strong ROE of 24.51% and ROA of 14.67%, indicating efficient use of equity and assets to generate profit.
- The company's liquidity position is strong with a current ratio of 3.23, but its negative net cash position raises concerns about short-term flexibility.
- Analysts have assigned a mean price target of $70.00, with a "buy" recommendation, suggesting a positive outlook for the stock.
- The company's risk profile is moderate, with medium liquidity risk and low dilution risk.
- No segment or geographic revenue breakdown is available, limiting the ability to assess concentration risks.
- The company's capital structure is relatively balanced, with a debt-to-equity ratio of 0.42.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | —no estimate |
| Revenue | —no estimate | —no estimate | 76,4M USD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Pro-Dex Inc Market data — financials · 2026-05-28
- Pro-Dex Inc Market data — analyst estimates · 2026-05-28
- Pro-Dex Inc Market data — ESG · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2024-06-300,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
- Director · Common StockOther 19 @ $33,25$632 · 2026-07-23
- Director, Chief Executive Officer · Common StockOther 5 279 @ $62,74$331K · 2026-07-01
- Chief Financial Officer · Common StockOther 10 800 · 2026-07-01
- Director · Common StockOther 2 488 @ $62,74$156K · 2026-07-01
- Director, Chief Executive Officer · Common StockOther 14 800 · 2026-07-01
- Director · Common StockOther 6 800 · 2026-07-01
- Chief Financial Officer · Common StockOther 3 897 @ $62,74$244K · 2026-07-01
- Director, Chief Executive Officer · Common StockSold 50 @ $63,63$3K · 2026-05-22
- Director, Chief Executive Officer · Common StockSold 1 254 @ $62,93$79K · 2026-05-22
- Director, Chief Executive Officer · Common StockSold 2 824 @ $62,09$175K · 2026-05-22
- Director, Chief Executive Officer · Common StockSold 550 @ $63,92$35K · 2026-05-21
- Director, Chief Executive Officer · Common StockSold 1 918 @ $62,22$119K · 2026-05-21
- Director, Chief Executive Officer · Common StockSold 3 404 @ $62,96$214K · 2026-05-21
- Director · Common StockSold 998 @ $47,24$47K · 2026-03-16
- Director · Common StockOther 18 @ $34,36$618 · 2026-01-22
- Director · Common StockOther 900 @ $32,73$29K · 2025-11-21
- Director · Common StockOther 2 200 @ $32,70$72K · 2025-11-21
- Chief Financial Officer · Common StockOther 72 @ $30,83$2K · 2025-11-20
- Director, Chief Executive Officer · Common StockOther 72 @ $30,83$2K · 2025-11-20
- Director, 10% owner · Common StockOther 1 000 · 2025-11-20
- Director · Common StockOther 1 000 · 2025-11-20
- Director · Common StockOther 1 000 · 2025-11-20
- Director · Common StockOther 1 000 · 2025-11-20
- Director · Common StockOther 72 @ $30,83$2K · 2025-11-20
- Director · Common StockOther 1 000 · 2025-11-20
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -27.8%Derived (calculated)
- Current ratio (FY 2025-12-31): 4.03xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.50xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 7,889.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 30.8%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
- Total assets (annual): USD 62.26MSEC XBRL filing
- Current liabilities (annual): USD 12.2MSEC XBRL filing
- Total liabilities (annual): USD 20.62MSEC XBRL filing
- Current assets (annual): USD 49.19MSEC XBRL filing
- Cash & equivalents (annual): USD 5.27MSEC XBRL filing
- Shareholders' equity (annual): USD 41.61MSEC XBRL filing
- Shares outstanding (annual): 3.21MSEC XBRL filing
- Net margin (FY 2025-06-30): 13.5%Derived (calculated)
- Revenue (YoY) (2025-06-30 vs 2024-06-30): 23.7%Derived (calculated)
- EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 347.5%Derived (calculated)
- Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): 19.8%Derived (calculated)
- Gross margin (FY 2025-06-30): 29.3%Derived (calculated)
- R&D expense (YoY) (2025-06-30 vs 2024-06-30): 14.0%Derived (calculated)
- Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -127.0%Derived (calculated)
- Net income (YoY) (2025-06-30 vs 2024-06-30): 322.1%Derived (calculated)
- Operating income (YoY) (2025-06-30 vs 2024-06-30): 49.0%Derived (calculated)
- Gross profit (YoY) (2025-06-30 vs 2024-06-30): 34.1%Derived (calculated)
- EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 345.0%Derived (calculated)